Dermatology Times: FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD

News

Dermatology Times: FDA Clears Zabalafin Hydrogel’s Investigational New Drug Application for AD by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics February 19, 2025 Alphyn Biologics announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for Zabalafin hydrogel, which is used to treat mild to moderate atopic…

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment

Press Release

Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…